Kendal Lilly
Primary Care · Findlay, OHNPI 1598474520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 27.5% of the total. 2025 is the largest year on record at $1,686, more than ten times the $67 reported in 2022. Among primary care clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$466
- AstraZeneca$404
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$315
- Pfizer$260
- Lilly USA, LLC$243
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,209100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 83 | $1,156 |
| Novo Nordisk | 31 | $466 |
| AstraZeneca | 12 | $404 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $315 |
| Pfizer | 18 | $260 |
| Lilly USA, LLC | 16 | $243 |
| Otsuka America Pharmaceutical, Inc. | 11 | $167 |
| Exact Sciences | 6 | $109 |
| GSK | 7 | $108 |
| Johnson & Johnson | 5 | $106 |
| Axsome Therapeutics, Inc. | 5 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Sumitomo Pharma America, Inc. | 6 | $98 |
| Phathom Pharmaceuticals, Inc. | 5 | $90 |
| Radius Health, Inc. | 5 | $84 |
| Actelion Pharmaceuticals US, Inc. | 3 | $70 |
| Amgen | 3 | $50 |
| Abbott | 2 | $36 |
| Harmony Biosciences LLC | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Shield Therapeutics Inc | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Athena Bioscience, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,209 in reported general payments places this provider in the 90th percentile of 321 primary care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $25,661 |
| OzempicSemaglutide | 12 | $15,940 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,856 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $6,642 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,249 |
| Pregabalin | 16 | $1,075 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,073 |
| Sertraline Hcl | 16 | $418 |
| Buspirone Hcl | 47 | $406 |
| Atorvastatin Calcium | 60 | $393 |
| Omeprazole | 67 | $391 |
| Pantoprazole Sodium | 26 | $290 |
| Trazodone Hcl | 19 | $261 |
| Fluticasone Propionate | 36 | $248 |
| Gabapentin | 37 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $243 | $25,66120 claims |
| Novo NordiskOzempic | $466 | $15,94012 claims |
| Boehringer IngelheimSpiriva Respimat | $14 | $9,85619 claims |
| GSKTrelegy Ellipta | $108 | $6,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 321 primary care providers in Ohio.
Other primary care in Findlay
- Regan HeagenFindlay$8K
- Alicia SaltzmanFindlay$3K
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Zachary HaleBeavercreek$7K
- Katherine ElliotWesterville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.